New drug hope for patients with rare bone cancer

Patients with a rare bone cancer of the skull and spine – chordoma – could be helped by existing PI3K inhibitor drugs, researchers suggest

New drug hope for patients with rare bone cancer

body_Chordoma.jpg
Sacral bone chordoma. Image credit: Dr Harry Gouvas

Patients with a rare bone cancer of the skull and spine – chordoma – could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today (12 October) in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors.

Researchers suggest a clinical trial of PI3K inhibitors for this particular group of chordoma patients, who could benefit from existing treatments.

Chordoma is a rare form of bone cancer that strikes individuals of all ages and affects 1 in every 800,000 people in the UK*. Chordomas are slow-growing, yet aggressive and life-threatening tumours that form in the vertebral bodies of the spine, the sacrum and base of the skull. The cancerous tumour is considered to develop from persistent embryonic tissue, known as the notochord.

As they involve critical structures such as the brainstem, spinal cord, and important nerves and arteries, chordomas are difficult to treat. Surgery and radiation are currently the only effective forms of treatment.

For the first time, scientists have used whole genome sequencing to gain a better understanding of the biology underlying chordoma. The results reveal promising new treatment options for a cancer with a poor prognosis.

The team studied chordoma tumours from 104 patients and found that 16 per cent of the tumour samples had genetic changes, or mutations, in PI3K signalling genes. These genes are the target of existing drugs, known as PI3K inhibitors, which are being used to treat many cancers, including breast cancer, lung cancer and lymphoma**, but have not yet been considered for chordoma.

The gene brachyury, or T, has been known for some time to play a role in chordoma but for the first time the team used genomic sequencing to demonstrate that only one additional copy of the T gene seems to drive these tumours. The team also discovered a new cancer gene that is specific to chordoma, known as LYST, which has not been found in any other cancer. This finding warrants future research.

“By sequencing the tumours’ DNA, we get a much clearer view of the genetic changes that drive chordoma. We have shown that a particular group of chordoma patients could be treated with PI3K inhibitors, based on their mutations. This would have been missed had we not done genomic sequencing of their tumours.”

Dr Sam Behjati, joint first author from the Wellcome Trust Sanger Institute

“These findings represent a major step forward in understanding the underlying causes of chordoma, and provide hope that better treatments may soon be available for some patients.”

Josh Sommer, a survivor of chordoma and Executive Director of the Chordoma Foundation, USA

“This study provides a resource for chordoma research for years to come. In the future we hope to target chordoma from three angles: trialling PI3K inhibitors in chordoma; developing a therapeutic approach to switching off the extra copy of the T gene and studying the function of LYST as a cancer gene and its role in the development of chordoma.”

Professor Adrienne Flanagan, joint lead author from the Royal National Orthopaedic Hospital NHS Trust and University College London Cancer Institute

Notes to Editors
Publications
  • The driver landscape of sporadic chordoma.

    Tarpey PS, Behjati S, Young MD, Martincorena I, Alexandrov LB et al.

    Nature communications 2017;8;1;890

Sources:

* https://www.bcrt.org.uk/information/information-by-type/chordoma/
** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708174/

Funding:

This work was supported by Wellcome, Skeletal Cancer Action Trust UK, Royal National Orthopaedic Hospital NHS Trust, Rosetrees Trust, Chordoma Foundation USA, Chordoma UK and the Terry Fox Research Institute.

Selected Websites
Pharmacogenomics and cancerStoriesPharmacogenomics and cancer
Pharmacogenomics is a specific kind of genetic testing that offers key advantages for doctors trying to choose the best drugs for their patients.

Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Wellcome Sanger Institute at 25: how the genomic revolution is changing medicine

Leaps forward in knowledge have allowed scientists and doctors to start to bringing advances out of the lab and into the clinic to directly benefit patients

LifeLab - Free events highlight discovery on your doorstep

Events include pop-up labs, a puppet show with a difference, story-telling and retro gameshows

International Vertebrate Genomes Project releases first 15 high-quality reference genomes

Publicly available data will impact studies on life, disease, and conservation efforts